Use of haploid model of Candida albicans to uncover mechanism of action of a novel antifungal agent
Files
(Published version)
Date
2018
Authors
Thuyen, T.
Suriyanarayanan, T.
Zeng, G.
Le, T.D.
Liu, L.
Li, J.
Tong, C.
Wang, Y.
Seneviratne, C.J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Frontiers in Cellular and Infection Microbiology, 2018; 8(164):1-14
Statement of Responsibility
Conference Name
Abstract
Antifungal agents for the treatment of Candida albicans infections are limited. We recently discovered a novel antifungal small molecule, SM21, with promising in vivo activity. Herein, we employed the newly developed C. albicans haploid toolbox to uncover the mechanism of action of SM21. Comprehensive RNA-Seq analyses of the haploid susceptible GZY803 strain revealed significant gene expression changes related to mitochondria when exposed to SM21. Mitochondria' structure visualization and measurement of ATP generation, reactive oxygen species (ROS) levels, and the antioxidant potential of SM21-treated and untreated GZY803, mitochondria' structure defective haploid mutant (dnml Delta), and wild-type diploid SC5314 strains confirmed defects in mitochondria. Exploiting the advantage of C. albicans haploids as a single ploidy model, we further exposed GZY803 to repetitive treatments of SM21 in order to generate resistant mutants. Three colonies designated S3, S5 and S6, which displayed resistance to SM21, were isolated. All resistant strains exhibited enhanced transcriptomic responses for peptide and protein metabolism and secreted aspartate proteases (SAPs) activity under SM21 treatment compared to the parent strain GZY803. Consistently, supplementing the resistant strains, GZY803, and SC5314 with peptone, a form of digested peptides, decreased susceptibility to SM21. The present study demonstrates the usefulness of haploid C. albicans model in antifungal drug discovery. The findings will be invaluable to develop SM21 as a novel antifungal agent, which will benefit millions of patients suffering from Candida infections.
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supplementary material, https://www.frontiersin.org/articles/10.3389/fcimb.2018.00164/full#supplementary-material
Access Status
Rights
Copyright 2018